Encompass Health (EHC) Stock Forecast & Price Target

Encompass Health is positioned for durable growth because its inpatient rehabilitation model serves non-discretionary, high-acuity demand in an under-supplied industry, and management continues to expand capacity through bed additions, de novos, and small-format hospitals. Fundamental momentum is strong: 3Q26 revenue rose 8.9% to $1.61 billion, adjusted EBITDA increased 15.5% to $346.6 million, margins improved to 21.5%, and guidance was raised to $6.45-$6.50 billion of revenue and $1.395-$1.415 billion of adjusted EBITDA. The outlook is further supported by 77.0% occupancy, 1.8x net leverage, improving labor costs, sustainable acuity-driven pricing, and meaningful tailwinds from VA growth, admit-and-appeal gains, and free cash flow that can fund buybacks and expansion.

Encompass Health is facing a negative fundamental backdrop because mature FFS providers are dealing with higher staffing costs, turnover, and reimbursement that generally lags, which compresses margins even as patient volume has recently recovered. The rebound in demand looks fragile, since CMS has generally issued more onerous reimbursement and regulatory provisions, Medicare Advantage payers may pressure admissions, and volume growth, de novo ramp-ups, and bed additions may all fall short of expectations. Financially, bad debt rose to 2.7% of revenue versus guidance of 2-2.5%, highlighting operational disruption from the Oracle billing conversion, while regulatory risk, labor shortages, and wage inflation further threaten profitability.